spacer
home > ict > Autumn 2019
PUBLICATIONS

International Clinical Trials

ict
Autumn 2019

   
Text
PDF
bullet
Features
Social Media in Orphan Disease Research

The New Imperative

Barbara Zupancic at Worldwide Clinical Trials evaluates the revolution of social media in clinical research and its newfound importance to the recruitment of rare and orphan disease subjects.
 
view
download pdf
Spotlight

A Landmark for Life Science Professionals

DIA Europe 2020 will be taking place in Brussels, bringing you expert insights into new trends and innovations in technology and research, with the patient perspective at the forefront of clinical research.
 
view
download pdf
Spotlight

The Spirit of Radical Integration

The Avoca Group is dedicated to enhancing the quality of clinical trial processes, mitigating risks, and providing innovative solutions by bringing together industry experts with their Quality Consortium.
 
view
download pdf
Clinical Trial Recruitment in Asia Pacific

The Pacific Rim

Dr Tracy Goeken at Linical Accelovance Group examines the benefits of conducting clinical trials in Asia Pacific, utilising its vast patient population and seeking to resolve the challenges of patient recruitment and retention.
 
view
download pdf
bullet
Therapeutic Focus: Dementia
Patient Registries in Dementia Trials

Early Detection for Invisible Patients

Professor Clive Ballard at the University of Exeter Medical School and Dr Dawie Wessels at Accelerated Enrollment Solutions discuss how patient registries can improve the detection of ‘invisible’ patients for dementia trials, presenting a new opportunity for prevention.
 
view
download pdf
Response Rates in Dementia Research

The Burden of Time

Minimising participant burden is essential to all medical research, and Shani McCoy at Berkshire Healthcare Foundation Trust assesses the factors that contribute to patient burden in dementia studies.
 
view
download pdf
New Frontiers in Alzheimer’s Disease Research

The Practical Alternative

The failures of Alzheimer’s disease research have opened up new approaches to achieve an earlier diagnosis and a more effective treatment approach, argues Timothy Earle at TauRx Theraputics.
 
view
download pdf
bullet
Innovative Trial Design
Guidance for Rare Disease Research

The Formula for Success

Dr Pavle Vukojevic, Dr Milan Marinkov, and Dr Jovana Vlajkovic- Josic at Pharm-Olam present a formula for success in improving recruitment, the accuracy of data, and streamlining rare disease clinical trials.
 
view
download pdf
Q&A: Clinical Trial Management Systems

Software Solutions

In a conversation with ICT, Ricky Lakhani at PHARMASEAL answers questions about the upcoming trends, benefits, and challenges in designing an effective trial management system using cloud-based software.
 
view
download pdf
bullet
Risk-Based Monitoring
Risk-Based Monitoring and Real-World Data

A Decentralised Ecosystem

There is an appetite for change in the capture, integration, and analysis of valuable data from human subjects, and Ian O’Shaughnessy at ICON explores the synergies between risk-based monitoring, decentralised clinical trials, and eSource.
 
view
download pdf
Clinical Data Management and Quality

A Paradigm Shift in Data Monitoring

François Torche at CluePoints examines the impact of regulations on data quality and management, addressing the need for more optimised monitoring approaches in clinical data science.
 
view
download pdf
Beyond Analytical Dashboards Without Context

Learning to Fish in Data Lakes

For Craig Morgan at Oracle Health Sciences, companies should seek new technology solutions for data monitoring, making effective use of analytical dashboards for powerful insights.
 
view
download pdf
   
spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

Sartorius Acquires Cell Culture Specialist Xell AG

The life science company Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany. Xell AG develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors that are used in gene therapeutics and vaccines
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement